Wells Fargo Maintains Equal-Weight on Alnylam Pharmaceuticals, Raises Price Target to $479

Benzinga · 11/11/2025 14:25
Wells Fargo analyst Derek Archila maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-Weight and raises the price target from $395 to $479.